“Sustained Complete Response to a Short Course of Subcutaneous Daratumumab in Multi-Refractory Immune Thrombocytopenia”, Mediterr J Hematol Infect Dis, vol. 18, no. 1, p. e2026069, Sep. 2026, doi: 10.4084/MJHID.2026.069.